Date: 2014-11-20
Type of information: Presentation of results at a congress
phase: 1-2
Announcement: presentation of results at the 14th International Conference on Progress in Vaccination against Cancer
Company: Medigene (Germany)
Product: Dendritic Cell (DC) vaccines
Action mechanism:
Disease: prostate cancer
Therapeutic area: Cancer - Oncology
Country: Norway
Trial details:
Latest
news: * On November 20, 2014, Medigene announced that an abstract on an investigator initiated phase II clinical trial with Medigene\'s DC vaccines for the treatment of prostate cancer currently being conducted by the Oslo University Hospital has been published in PIVAC-14 abstract book (p. 17 of the abstract book). Currently Medigene\'s DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML in 2014.
